VEGFA and neoplasm: This work is of particular significance with the advent of anti-vascular endothelial growth factor antibody Bevazucimab (Avastin, Gentec, South Francisco, CA, USA) and the realisation that its mechanism of anti-tumour activity is primarily due to normalisation of tumour vessels (Willett et al, 2004).